Increase of plasma VEGF after intravenous administration of bevacizumab is predicted by a pharmacokinetic model

Marianne O. Stefanini, Florence T H Wu, Feilim Mac Gabhann, Aleksander S Popel

Research output: Contribution to journalArticle

Abstract

Vascular endothelial growth factor (VEGF) is one of the most potent cytokines targeted in antiangiogenic therapies. Bevacizumab, a recombinant humanized monoclonal antibody to VEGF, is being used clinically in combination with chemotherapy for colorectal, non-small cell lung and breast cancers, and as a single agent for glioblastoma and is being tested for other types of cancer in numerous clinical trials. It has been reported that the intravenous injection of bevacizumab leads to an increase of plasma VEGF concentration in cancer patients. The mechanism responsible for this counterintuitive increase has not been elucidated, although several hypotheses have been proposed. We use a multiscale systems biology approach to address this problem. We have constructed a whole-body pharmacokinetic model comprising three compartments: blood, normal tissue, and tumor tissue. Molecular interactions among VEGF-A family members, their major receptors, the extracellular matrix, and an anti-VEGF ligand are considered for each compartment. Diffusible molecules extravasate, intravasate, are removed from the healthy tissue through the lymphatics, and are cleared from the blood.

Original languageEnglish (US)
Pages (from-to)9886-9894
Number of pages9
JournalCancer Research
Volume70
Issue number23
DOIs
StatePublished - Dec 1 2010

Fingerprint

Intravenous Administration
Vascular Endothelial Growth Factor A
Pharmacokinetics
Antibodies, Monoclonal, Humanized
Neoplasms
Systems Biology
Lymphoid Tissue
Glioblastoma
Combination Drug Therapy
Non-Small Cell Lung Carcinoma
Intravenous Injections
Bevacizumab
Clinical Trials
Breast Neoplasms
Cytokines
Ligands
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Increase of plasma VEGF after intravenous administration of bevacizumab is predicted by a pharmacokinetic model. / Stefanini, Marianne O.; Wu, Florence T H; Mac Gabhann, Feilim; Popel, Aleksander S.

In: Cancer Research, Vol. 70, No. 23, 01.12.2010, p. 9886-9894.

Research output: Contribution to journalArticle

Stefanini, Marianne O. ; Wu, Florence T H ; Mac Gabhann, Feilim ; Popel, Aleksander S. / Increase of plasma VEGF after intravenous administration of bevacizumab is predicted by a pharmacokinetic model. In: Cancer Research. 2010 ; Vol. 70, No. 23. pp. 9886-9894.
@article{b68f6cfa1b9544fc842ef1ceebc40d89,
title = "Increase of plasma VEGF after intravenous administration of bevacizumab is predicted by a pharmacokinetic model",
abstract = "Vascular endothelial growth factor (VEGF) is one of the most potent cytokines targeted in antiangiogenic therapies. Bevacizumab, a recombinant humanized monoclonal antibody to VEGF, is being used clinically in combination with chemotherapy for colorectal, non-small cell lung and breast cancers, and as a single agent for glioblastoma and is being tested for other types of cancer in numerous clinical trials. It has been reported that the intravenous injection of bevacizumab leads to an increase of plasma VEGF concentration in cancer patients. The mechanism responsible for this counterintuitive increase has not been elucidated, although several hypotheses have been proposed. We use a multiscale systems biology approach to address this problem. We have constructed a whole-body pharmacokinetic model comprising three compartments: blood, normal tissue, and tumor tissue. Molecular interactions among VEGF-A family members, their major receptors, the extracellular matrix, and an anti-VEGF ligand are considered for each compartment. Diffusible molecules extravasate, intravasate, are removed from the healthy tissue through the lymphatics, and are cleared from the blood.",
author = "Stefanini, {Marianne O.} and Wu, {Florence T H} and {Mac Gabhann}, Feilim and Popel, {Aleksander S}",
year = "2010",
month = "12",
day = "1",
doi = "10.1158/0008-5472.CAN-10-1419",
language = "English (US)",
volume = "70",
pages = "9886--9894",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "23",

}

TY - JOUR

T1 - Increase of plasma VEGF after intravenous administration of bevacizumab is predicted by a pharmacokinetic model

AU - Stefanini, Marianne O.

AU - Wu, Florence T H

AU - Mac Gabhann, Feilim

AU - Popel, Aleksander S

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Vascular endothelial growth factor (VEGF) is one of the most potent cytokines targeted in antiangiogenic therapies. Bevacizumab, a recombinant humanized monoclonal antibody to VEGF, is being used clinically in combination with chemotherapy for colorectal, non-small cell lung and breast cancers, and as a single agent for glioblastoma and is being tested for other types of cancer in numerous clinical trials. It has been reported that the intravenous injection of bevacizumab leads to an increase of plasma VEGF concentration in cancer patients. The mechanism responsible for this counterintuitive increase has not been elucidated, although several hypotheses have been proposed. We use a multiscale systems biology approach to address this problem. We have constructed a whole-body pharmacokinetic model comprising three compartments: blood, normal tissue, and tumor tissue. Molecular interactions among VEGF-A family members, their major receptors, the extracellular matrix, and an anti-VEGF ligand are considered for each compartment. Diffusible molecules extravasate, intravasate, are removed from the healthy tissue through the lymphatics, and are cleared from the blood.

AB - Vascular endothelial growth factor (VEGF) is one of the most potent cytokines targeted in antiangiogenic therapies. Bevacizumab, a recombinant humanized monoclonal antibody to VEGF, is being used clinically in combination with chemotherapy for colorectal, non-small cell lung and breast cancers, and as a single agent for glioblastoma and is being tested for other types of cancer in numerous clinical trials. It has been reported that the intravenous injection of bevacizumab leads to an increase of plasma VEGF concentration in cancer patients. The mechanism responsible for this counterintuitive increase has not been elucidated, although several hypotheses have been proposed. We use a multiscale systems biology approach to address this problem. We have constructed a whole-body pharmacokinetic model comprising three compartments: blood, normal tissue, and tumor tissue. Molecular interactions among VEGF-A family members, their major receptors, the extracellular matrix, and an anti-VEGF ligand are considered for each compartment. Diffusible molecules extravasate, intravasate, are removed from the healthy tissue through the lymphatics, and are cleared from the blood.

UR - http://www.scopus.com/inward/record.url?scp=78649952814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649952814&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-10-1419

DO - 10.1158/0008-5472.CAN-10-1419

M3 - Article

VL - 70

SP - 9886

EP - 9894

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 23

ER -